국가임상시험지원재단

 Digital healthcare technology is moving beyond the consumer market. The healthcare wearables device market could more than triple to $18.9 billion in 2020 from $5.1 billion in 2015. The healthcare and pharmaceutical industries are fully embracing trekking to monitor patients between visits, improve patient adherence to medications and accelerate clinical drug trials. Wearable devices can give clinical physicians insights into patient behavior and disease progression through a steady flow of electronic data transmitted by the devices. Digital healthcare devices also enable clinicians and pharmaceutical companies conducting drug trials to collect more patient-generated health data and contribute to ongoing population health analytics.
As the healthcare industry transitions from “fee for service” to a value-based model, especially in Korea, that emphasizes preventative health, patient-centered care and reduced costs, wearable medical devices are extending the ability of providers to collect real-time patient health data and assess patient medication adherence. Wearables also will generate valuable population data that can be used for medical and population health research. Applying digital healthcare devices to clinical trials is not to prove something new, but to improve the quality of clinical trials.
1. Keep monitoring : Healthcare analytics company PhysIQ recently launched a pilot study at Partners HealthCare Brigham and Women’s Hospital (BWH) in Boston to determine whether clinician visits to patient homes, coupled with advanced continuous electronic digital patient monitoring, can be used to avoid hospitalizations. Patients diagnosed at the BWH emergency department with complications related to heart failure, pneumonia, COPD and several other conditions are being provided with advanced monitoring technology, including a wearable patch, to provide clinicians with continuous patient medical data. Remote monitoring will make a difference.
2. Cost saving: Digital health can be used not only to improve patient and population health, but also to reduce healthcare costs. A study published in The American Journal of Managed Care recently analyzed anonymized medical and pharmacy claims data from more than 1.2 million patients who have diabetes, high blood pressure or high cholesterol - all among the most expensive chronic diseases to treat. An analysis by the CVS Health Research Institute concluded that payers could save approximately $38 million to $63 million per 100,000 members by deploying resources for improving medication adherence in specific patient populations.
As the healthcare industry transitions from “fee for service” to a value-based model, especially in Korea, that emphasizes preventative health, patient-centered care and reduced costs, wearable medical devices are extending the ability of providers to collect real-time patient health data and assess patient medication adherence. Wearables also will generate valuable population data that can be used for medical and population health research. Applying digital healthcare devices to clinical trials is not to prove something new, but to improve the quality of clinical trials.?

 Kwang Joon Kim (Yonsei University College of Medicine, Korea)

상기 과정은 직능별, 단계별 인정가능시간이 상이하며 인정가능시간은 다음의 별표를 확인하시기 바랍니다.

[별표 1]

임상시험등 종사자별 교육과정 및 이수시간

(제5조 관련)